
Ferrer, Leti and Oryzon to collaborate in R&D
Catalan Economy
21 Nov 2009
Pharmaceutical companies Ferrer and Leti and biotech firm Oryzon have announced the creation of the Oncochip alliance to further develop cancer research in Catalonia. Madrid-based Ingenasa and Navarra’s CIMA are also to participate in the project.
With a budget of over EUR 20 million, Oncochip will focus on the design of therapies for early diagnosis of ovarian cancer, melanoma and colon cancer. Oryzon specializes in the detection of cancer biomarkers and is already working with Reig Jofré on uterine cancer research.
Ferrer, Leti and Oryzon also plan to create a new partnership next year to develop nanotechnology projects.
Source: Expansión Cataluña 16/11/2009
Related News and Success stories.
-
22 Sep 2025
HIPRA opens new €500M Biotech campus in Catalonia, strengthening Europe’s Life Sciences hub
-
18 Sep 2025
DHL Express inaugurates new €80M international hub in Barcelona
-
15 Sep 2025
Trace ID opens new 2,000 m2 chip welding plant in Barcelona, a European first
-
12 Sep 2025
Barcelona Emerges as a Global Top 3 Hub for AI Investment